New insight in improving therapeutic efficacy of antipsychotic agents

An overview of improved in vitro and in vivo performance, efficacy upgradation and future prospects

Hnin Ei Thu, Zahid Hussain, Ahmad Nazrun Shuid

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Psychotic disorders are recognized as severe mental disorders that rigorously affect pa-tient’s personality, critical thinking, and perceptional ability. High prevalence, global dissemination and limitations of conventional pharmacological approaches compel a significant burden to the patient, medical professionals and the healthcare system. To date, numerous orally administered therapies are available for the management of depressive disorders, schizophrenia, anxiety, bipolar disorders and autism spectrum problems. However, poor water solubility, erratic oral absorption, extensive first-pass metabolism, low oral bioavailability and short half-lives are the major factors which limit the pharmaceutical significance and therapeutic feasibility of these agents. In recent decades, nanotechnology-based delivery systems have gained remarkable attention of the researchers to mitigate the pharmaceutical issues related to the antipsychotic therapies and to optimize their oral drug delivery, therapeutic outcomes, and patient compliance. Therefore, the present review was aimed to summarize the available in vitro and in vivo evidences signifying the pharmaceutical importance of the advanced delivery systems in improving the aqueous solubility, transmembrane permeability, oral bioavailability and therapeutic outcome of the antipsychotic agents.

Original languageEnglish
Pages (from-to)865-876
Number of pages12
JournalCurrent Drug Targets
Volume19
Issue number8
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Antipsychotic Agents
Solubility
Pharmaceutical Preparations
Biological Availability
Drug delivery
Nanotechnology
Metabolism
Therapeutics
Aptitude
Patient Compliance
Depressive Disorder
Autistic Disorder
Anxiety Disorders
Bipolar Disorder
Mental Disorders
Water
Psychotic Disorders
Personality
Permeability
Schizophrenia

Keywords

  • Antipsychotic agents
  • Aqueous solubility
  • Efficacy-upgradation
  • Nanotechnology
  • Oral bioavailability
  • Pharmacokinetic profile
  • Psychiatric disorders

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

@article{f3bf8507982543258ad5e0169ae16eb7,
title = "New insight in improving therapeutic efficacy of antipsychotic agents: An overview of improved in vitro and in vivo performance, efficacy upgradation and future prospects",
abstract = "Psychotic disorders are recognized as severe mental disorders that rigorously affect pa-tient’s personality, critical thinking, and perceptional ability. High prevalence, global dissemination and limitations of conventional pharmacological approaches compel a significant burden to the patient, medical professionals and the healthcare system. To date, numerous orally administered therapies are available for the management of depressive disorders, schizophrenia, anxiety, bipolar disorders and autism spectrum problems. However, poor water solubility, erratic oral absorption, extensive first-pass metabolism, low oral bioavailability and short half-lives are the major factors which limit the pharmaceutical significance and therapeutic feasibility of these agents. In recent decades, nanotechnology-based delivery systems have gained remarkable attention of the researchers to mitigate the pharmaceutical issues related to the antipsychotic therapies and to optimize their oral drug delivery, therapeutic outcomes, and patient compliance. Therefore, the present review was aimed to summarize the available in vitro and in vivo evidences signifying the pharmaceutical importance of the advanced delivery systems in improving the aqueous solubility, transmembrane permeability, oral bioavailability and therapeutic outcome of the antipsychotic agents.",
keywords = "Antipsychotic agents, Aqueous solubility, Efficacy-upgradation, Nanotechnology, Oral bioavailability, Pharmacokinetic profile, Psychiatric disorders",
author = "{Ei Thu}, Hnin and Zahid Hussain and Shuid, {Ahmad Nazrun}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1389450117666161125174625",
language = "English",
volume = "19",
pages = "865--876",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - New insight in improving therapeutic efficacy of antipsychotic agents

T2 - An overview of improved in vitro and in vivo performance, efficacy upgradation and future prospects

AU - Ei Thu, Hnin

AU - Hussain, Zahid

AU - Shuid, Ahmad Nazrun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Psychotic disorders are recognized as severe mental disorders that rigorously affect pa-tient’s personality, critical thinking, and perceptional ability. High prevalence, global dissemination and limitations of conventional pharmacological approaches compel a significant burden to the patient, medical professionals and the healthcare system. To date, numerous orally administered therapies are available for the management of depressive disorders, schizophrenia, anxiety, bipolar disorders and autism spectrum problems. However, poor water solubility, erratic oral absorption, extensive first-pass metabolism, low oral bioavailability and short half-lives are the major factors which limit the pharmaceutical significance and therapeutic feasibility of these agents. In recent decades, nanotechnology-based delivery systems have gained remarkable attention of the researchers to mitigate the pharmaceutical issues related to the antipsychotic therapies and to optimize their oral drug delivery, therapeutic outcomes, and patient compliance. Therefore, the present review was aimed to summarize the available in vitro and in vivo evidences signifying the pharmaceutical importance of the advanced delivery systems in improving the aqueous solubility, transmembrane permeability, oral bioavailability and therapeutic outcome of the antipsychotic agents.

AB - Psychotic disorders are recognized as severe mental disorders that rigorously affect pa-tient’s personality, critical thinking, and perceptional ability. High prevalence, global dissemination and limitations of conventional pharmacological approaches compel a significant burden to the patient, medical professionals and the healthcare system. To date, numerous orally administered therapies are available for the management of depressive disorders, schizophrenia, anxiety, bipolar disorders and autism spectrum problems. However, poor water solubility, erratic oral absorption, extensive first-pass metabolism, low oral bioavailability and short half-lives are the major factors which limit the pharmaceutical significance and therapeutic feasibility of these agents. In recent decades, nanotechnology-based delivery systems have gained remarkable attention of the researchers to mitigate the pharmaceutical issues related to the antipsychotic therapies and to optimize their oral drug delivery, therapeutic outcomes, and patient compliance. Therefore, the present review was aimed to summarize the available in vitro and in vivo evidences signifying the pharmaceutical importance of the advanced delivery systems in improving the aqueous solubility, transmembrane permeability, oral bioavailability and therapeutic outcome of the antipsychotic agents.

KW - Antipsychotic agents

KW - Aqueous solubility

KW - Efficacy-upgradation

KW - Nanotechnology

KW - Oral bioavailability

KW - Pharmacokinetic profile

KW - Psychiatric disorders

UR - http://www.scopus.com/inward/record.url?scp=85048981535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048981535&partnerID=8YFLogxK

U2 - 10.2174/1389450117666161125174625

DO - 10.2174/1389450117666161125174625

M3 - Review article

VL - 19

SP - 865

EP - 876

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 8

ER -